ArticleDermatology and therapy2026

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks.

Howard L Sofen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.